CST >325 μm will be used as a marker of DME activity as preclinical data suggest that dual Ang-2/VEGF-A inhibition may promote vascular integrity and reduce retinal edema compared with VEGF inhibition alone [19]. The gene discussed is VEGFA; the disease is retinal edema.